Akero Q2 2020 Earnings Report
Key Takeaways
Akero Therapeutics reported positive histological results for their FGF21 analog, efruxifermin (EFX), observing improvements in NASH histological parameters after 16 weeks of treatment. Clinically meaningful improvements in glycemic control, weight loss, and lipoproteins were also observed in the BALANCED study.
Reported first histological results for efruxifermin (EFX).
Observed improvements in histological parameters of NASH after only 16 weeks of treatment.
Observed significant reductions in HbA1c and body weight in biopsy-confirmed NASH patients following EFX treatment.
Observed significant 12-14% absolute reductions (corresponding to 63-72% relative reductions) in liver fat.
Akero
Akero
Forward Guidance
Akero is dedicated to reversing the escalating NASH epidemic by developing pioneering medicines designed to restore metabolic balance and improve overall health of NASH patients.